⚡ Syringe Tool
Metabolic & Fat Loss FDA Approved (Specific Indications) PubChem CID: 16135400

Tirzepatide: Clinical Mechanism, Dossier & Protocols

Dual GIP and GLP-1 receptor agonist engineered with a 39-amino acid modified sequence and C20 fatty diacid moiety that delivers profound metabolic control and fat loss.

Reconstitution Guide Syringe Calculator BAC Water Guide

🔬 Molecular Architecture & Physical Specifications

Molecular Weight
4813.45 g/mol
Chemical Formula
C225H348N48O68
CAS Registry Number
2023788-19-2
Elimination Half-Life
Approx. 5 days
Administration Route
Subcutaneous (SC)
NCBI PubChem Record
Amino Acid Sequence: Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQKAFVQWLIAGGPSSGAPPPS-NH2 (conjugated with C20 diacid)

⚙️ Primary Mechanism of Action

Synergistically stimulates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon postprandially, delaying gastric emptying, and reducing caloric intake.

💉 Research Dosage & Reconstitution Standard

Requires pharmaceutical-grade 0.9% benzyl alcohol Bacteriostatic Water to inhibit bacterial replication for multi-dose access.

Full Step-by-Step Guide →
Standard Vial Sizes
5mg, 10mg, 15mg, 30mg
Target Research Dose
2.5mg weekly initiation, titrating every 4 weeks to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg
Administration Frequency
Once weekly
💧 Dilution Standard: Reconstitute with sterile Bacteriostatic Water for Injection (USP). Aim stream gently along the vial glass wall to avoid foaming. Store reconstituted solution at 2°C to 8°C (36°F to 46°F) protected from light. Discard multi-dose punctured vials at 28 days pursuant to USP <797> standards. Never freeze reconstituted liquid.

⚠️ Contraindications & Documented Adverse Effects

Strict Contraindications

  • History of MTC
  • MEN 2
  • Pregnancy
  • History of gastroparesis

Documented Side Effects

  • Nausea
  • Vomiting
  • Constipation
  • Acid reflux/heartburn
  • Fatigue in early titration

📚 Peer-Reviewed References & Authoritative Sources

Citations indexed in PubMed, National Center for Biotechnology Information (NCBI), and ClinicalTrials.gov.

3 VERIFIED CITATIONS
New England Journal of Medicine (NEJM 2022; 387:205-216)
Phase 3 randomized trial in 2,539 adults demonstrating up to 22.5% average weight reduction at 72 weeks with 15mg weekly dosing.
PMID: 35658024 · DOI: 10.1056/NEJMoa2206038
New England Journal of Medicine (NEJM 2021; 385:503-515)
Head-to-head clinical trial showing Tirzepatide produced superior reductions in HbA1c and body weight compared to 1.0mg Semaglutide.
PMID: 34170647 · DOI: 10.1056/NEJMoa2107519
U.S. Food and Drug Administration (FDA Center for Drug Evaluation and Research)
Official FDA prescribing information, clinical pharmacology review, and pharmacovigilance documentation.

⚖️ Head-to-Head Comparisons Featuring Tirzepatide

Retatrutide vs Tirzepatide: Triple Agonist vs Dual Incretin Comparison

Retatrutide demonstrates superior peak weight loss (up to 24.2% in Phase 2) and accelerated liver fat clearance due to i...

Read Showdown →

Tirzepatide vs Semaglutide: Dual Agonist vs Single GLP-1 Efficacy

In head-to-head SURPASS-2 trials, Tirzepatide delivered statistically significant superior weight reduction (approx. 20....

Read Showdown →

Explore Related Research Modules

Access exact dilution guides, syringe unit calculators, and purity certificates for Tirzepatide.

💧 Tirzepatide Dilution Guide ⚡ Syringe Reconstitution Tool Bacteriostatic Water Monograph Tested Vendor Directory Cycle Cost Calculator